Pharmacyte Biotech, Inc. (PMCB) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the Annual Meeting of Stockholders held on April 29, 2024, for Pharmacyte Biotech, Inc. The meeting covered the fiscal year ended April 30, 2024. The company is incorporated in Nevada and its common stock trades on The Nasdaq Stock Market LLC under the symbol PMCB.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
A quorum was established with 4,514,887 shares represented, approximately 53.41% of outstanding shares entitled to vote. Stockholders approved three proposals:
- Proposal 1: Election of Directors - Five nominees were elected to serve until the 2025 annual meeting. All nominees received majority support, though Michael M. Abecassis received the highest number of withheld votes (579,651).
- Proposal 2: Ratification of Auditor - Stockholders ratified the selection of Marcum LLP as the independent registered public accounting firm for the fiscal year ending April 30, 2024. Votes were 4,387,273 For, 109,167 Against, and 18,447 Abstain.
- Proposal 3: Executive Compensation - The advisory vote on named executive officer compensation was approved. Votes were 1,922,352 For, 186,215 Against, and 50,866 Abstain. There were 2,355,454 broker non-votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items beyond the standard disclosure of the voting process.
Investor Verification Checklist
- Verify the definitive proxy statement filed on March 27, 2024, for detailed biographies of the elected directors and the rationale for executive compensation.
- Review the company's most recent 10-K or 10-Q for financial performance data, as this 8-K contains no financial metrics.
- Monitor the company's leadership structure, noting that Joshua N. Silverman signed the report as Interim Chief Executive Officer and Interim President.
- Confirm the tenure of the newly elected board members, which extends until the 2025 annual meeting.